Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma & IT stocks lead the gains
Fri, 28 Feb 11:30 am

After opening firm, the Indian indices are above the dotted line in the morning session. Apart from energy stocks, most of the sectoral indices are trading in the green led by pharma and software stocks.

The BSE-Sensex is trading up 105 points and the NSE-Nifty is trading up 25 points. The BSE Mid Cap index is trading up 0.5% and the BSE Small Cap index is trading up 0.4%. The rupee is trading at 62.08 to the US dollar.

Retail stocks are trading mixed today. While Zodiac Cloth is leading the gainers, Titan is leading the losers. India's leading consumer firm, Titan, has announced its 3QFY14 results. The company has reported an 11.1% YoY fall in sales on the back of a subdued performance in the watches and jewellery segments. Despite the poor topline performance, the operating margin was flat for the quarter at 7.7%. However, higher interest costs and lower other income took a toll on the bottomline. The net profit of the company fell by 18% YoY despite a fall in the tax rate. Titan is trading down 0.6% today.

Most mining stocks are currently trading firm. Ashapura Minechem and Coal India are leading the gainers. Coal India has announced its 3QFY14 results. Coal production was flat while offtake was marginally lower on a YoY basis, in the quarter. Net sales declined by 2.3% YoY. The operating profit fell by 4.3% YoY thus lowering the operating margin by 1% YoY. Apart from the muted operating performance, a fall in other income by 7.5% YoY also impacted the bottomline. The net profit of the company fell by 18% YoY and the net margin fell by 2% YoY. Coal India is trading higher by 1% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma & IT stocks lead the gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.